MILAN, Sept. 21, 2023 /PRNewswire/ — Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Subtle Medical, Inc., a leading innovator in artificial intelligence (AI)-powered image acquisition, have entered into a global agreement in the field of magnetic resonance imaging (MRI). This global agreement will begin primarily in the United States, where Bracco […]
Tag: Bracco
Bracco Diagnostics Inc. Announces New Partnership to Increase Access to Cardiac PET Imaging
MONROE TOWNSHIP, N.J., March 29, 2021 /PRNewswire/ — Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today a new partnership with CardioNavix, LLC aimed at improving patient access to cardiac PET imaging, an important diagnostic test for the detection of coronary […]
Bracco Announces U.S. FDA Approval of 20-Vial Configuration of LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use
20-vial pack provides a green packaging alternative and helps increase storage efficiency MONROE TOWNSHIP, N.J., Feb. 22, 2021 /PRNewswire/ — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that its ultrasound enhancing agent (UEA) LUMASON® (sulfur hexafluoride lipid-type […]
Bracco Diagnostics Inc. Introduces New CardioGen-82® (Rubidium Rb 82 Generator) Infusion System
MONROE TOWNSHIP, N.J., Oct. 16, 2020 /PRNewswire/ — Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today the FDA approval of its new CardioGen-82 infusion system to enhance automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). […]
Bracco Diagnostics Inc.’s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, receives U.S. Food and Drug Administration approval for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in pediatric patients with suboptimal echocardiograms
MONROE TOWNSHIP, N.J., Dec. 2, 2019 /PRNewswire/ — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that its contrast agent LUMASON is the first ultrasound enhancing agent (UEA) to obtain U.S. Food and Drug Administration (FDA) approval for […]



